Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II double-blind randomized placebo-controlled study of DC521022 in relapsing-remitting multiple sclerosis
CTR20262072Phase 2Active
- Sponsor
- Shanghai Institute of Materia Medica
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of DC521022 in multiple sclerosis (MS), sponsored by Shanghai Institute of Materia Medica. Started Jun 2026; status: active.
02
Drugs
DC521022
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on CTR20262072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262072.